Evidence map›Paper›PMID 42763926›Full record

ArticleChemistry & biodiversity2026

Design, Synthesis, and Evaluation of New 1,4-Naphthoquinone-1,2,3-triazoles as Antimalarial Agents.

Lina Rezainia, Mohammad Hosein Sayahi, Eisa Kaveh Vernousfaderani, Seyedeh Sara Mirfazli, Mohammad Hossein Morshedsolouk, Navid Dastyafteh, Mehdi Nateghpour, Leila Farivar, Mina Saeedi, Haleh Hanifian and 4 more

Abstract read
In one paragraph

Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lina RezainiaEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Hosein SayahiDepartment of Chemistry, Payame Noor University, Tehran, Iran.
Eisa Kaveh VernousfaderaniDepartment of Pharmacology and Toxicology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-1429-775X
Seyedeh Sara MirfazliDepartment of Medicinal Chemistry, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0001-7171-683X
Mohammad Hossein MorshedsoloukEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0001-8233-9785
Navid DastyaftehEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Mehdi NateghpourDepartment of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences (TUMS), Tehran, Iran.ORCID https://orcid.org/0000-0002-8403-8190
Leila FarivarCenter For Research of Endemic Parasites of Iran, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Mina SaeediPersian Medicine and Pharmacy Research Center, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-9046-8058
Haleh HanifianDepartment of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences (TUMS), Tehran, Iran.ORCID https://orcid.org/0000-0001-6773-9959
Mahdi MohebaliDepartment of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Seyedeh Mana ShafieeDepartment of Medicinal Chemistry, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0009-0007-0914-806X
Gholamreza HassanpourCenter For Research of Endemic Parasites of Iran, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Mohammad MahdaviEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-4171-7310

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increasing resistance to existing antimalarial agents has prompted researchers to develop new therapeutic candidates. To address this, the hybridization of 1,4-naphthoquinone and 1,2,3-triazole yielded a new series of compounds evaluated as prospective in vitro antimalarial agents against the chloroquine-sensitive 3D7 and chloroquine-resistant K1 strains of Plasmodium falciparum. The target compounds were synthesized efficiently via a multistep route, involving the reaction of 1,4-naphthoquinone and p-aminobenzoic acid, followed by reactions with propargylamine and different prepared chlorides. The synthetic route was concluded using a copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) "click" reaction. Based on structure-activity relationships (SAR), the compound bearing a 4-chloroaryl moiety (9g) was the most active against P. falciparum 3D7, exhibiting 60.00% growth inhibition at 25 µM. Furthermore, compound 9k bearing a 2-methylaryl moiety exhibited the most potent activity against P. falciparum K1, showing 64.52% growth inhibition at 50 µM. In silico simulations of compound 9g on thirteen protein targets in P. falciparum indicated strong interactions with the 1J3 and 1LDG targets. Also, the stability of the ligand-protein complexes was verified for 3FGO.

Indexed as

AntimalarialsDrug DesignNaphthoquinonesPlasmodium falciparumTriazolesHumansMolecular StructureParasitic Sensitivity TestsStructure-Activity Relationship1,4-naphthoquinoneAntimalarialsNaphthoquinonesTriazoles1,2,3‐triazole1,4‐naphthoquinoneantimalarialclick reactiondynamic studiesPlasmodium falciparum

Identifiers

PMID42763926
PMCPMC13590129

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.